77771-03-0

Basic information

• Product Name: 3-Bromo-4-fluorobenzylamine hydrochloride
• Synonyms: 3-Bromo-4-fluorobenzyl alcohol 99%;RARECHEM AL BD 0277;3-BROMO-4-FLUOROBENZYL ALCOHOL;(3-BROMO-4-FLUORO-PHENYL)-METHANOL;3-BROMO-4-FLUOROBENZYLAMINE HYDROCHLORIDE 98%;3-Bromo-4-fluorobenzylamine hydrochloride;3-Bromo-4-fluorobenzylamine hydrochloride,98%
• CAS NO: 77771-03-0
• Molecular Formula: C₇H₆BrFO
• Molecular Weight: 240.5
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Anilines, Aromatic Amines and Nitro Compounds;Alcohols;Bromine Compounds;Fluorine Compounds;Anilines, Amides & Amines;Fluorine series
• Mol File: 77771-03-0.mol

Chemical Properties

• Melting Point: 214 °C
• Boiling Point: 80°C/0.5mm
• Flash Point: 105.3 °C
• Appearance: Yellow/Powder
• Density: 1.658±0.06 g/cm3(Predicted)
• Vapor Pressure: 0.0216mmHg at 25°C
• Refractive Index: 1.5590 to 1.5630
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.83±0.10(Predicted)
• Water Solubility: soluble
• CAS DataBase Reference: 3-Bromo-4-fluorobenzylamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-4-fluorobenzylamine hydrochloride(77771-03-0)
• EPA Substance Registry System: 3-Bromo-4-fluorobenzylamine hydrochloride(77771-03-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-24/25
• Hazardous Substances Data: 77771-03-0(Hazardous Substances Data)

Usage

Chemical Properties

YELLOW POWDER

InChI:InChI:1S/C7H7BrFN.ClH/c8-6-3-5(4-10)1-2-7(6)9;/h1-3H,4,10H2;1H

Upstream product

• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 103-83-3 N,N'-dimethylbenzylamine 
• 1007-16-5 3-bromo-4-fluorobenzoic acid 
• 5197-95-5 benzyltriethylammonium bromide 
• 541-41-3 chloroformic acid ethyl ester 
• 1634-04-4 tert-butyl methyl ether 
• 79-22-1 methyl chloroformate 
• 16940-66-2 sodium tetrahydroborate 
• 78239-65-3 3-bromo-4-fluoro-benzoic acid fluoride 
• 206551-41-9 2-fluoro-3-bromobenzoic acid methyl ester 
• 82702-31-6 methyl 3-bromo-4-fluorobenzoate 

Downstream Products

• 887268-22-6 2-bromo-1-fluoro-4-(methoxymethyl)benzene 
• 1248085-09-7 C₁₀H₁₂BrFO₂ 
• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 78239-71-1 3-bromo-4-fluorobenzyl bromide 
• 866862-23-9 3-bromo-4-fluorobenzyl metanesulfonate 
• 1120371-01-8 (E)-1-(3-bromo-4-fluorophenyl)-2-methylbut-2-en-1-ol 
• 1159894-71-9 2-(3-bromo-4-fluoro-benzyloxy)-tetrahydropyrane 
• 1297551-06-4 ethyl 2-(3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}-4-fluorophenyl)-trans-cyclopropanecarboxylate 
• 1147334-61-9 ethyl 3-(3-bromo-4-fluorophenyl)acrylate 
• 501420-63-9 2-(3-bromo-4-fluoro-phenyl)acetonitrile 
• 1609540-78-4 5-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzoic acid 
• 1609540-85-3 5-(((tert-butyldimethylsilyl)oxy)methyl)-2-fluorobenzaldehyde 
• 1609540-89-7 tert-butyl((4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)dimethylsilane 
• 13294-41-2 (3-bromo-4-fluorophenyl)(phenyl)methanone 

Relevant articles and documents

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

Synthesis of structurally diverse diarylketones through the diarylmethyl sp3 C-H oxidation

Under open-flask conditions, an efficient method to assemble a series of diversely functionalized diarylketones in the presence of commercially available NBS has been developed. Yields of up to 99% have been achieved employing diarylmethanes as starting material. Based on 18O-labeled experiment, the addition of stoichiometric water eventually leads to excellent yields in all carbonylation cases.

Synthesis of benzyl alcohol building blocks bearing an aldehyde, pinacol borane or carboxylic acid motif via lithium-bromide exchange

A range of useful disubstituted benzyl alcohol building blocks have been synthesised in multigram quantities in a lithium-bromide exchange to give aldehyde, carboxylic acid and pinacol -boranes in high yields. Georg Thieme Verlag Stuttgart · New York.

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

METHOD FOR PRODUCING PRECURSORS FOR L-2- [18F] FLUOROPHENYLALANINE AND 6- [18F] FLUORO-L--META-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-2- [18F] FLUOROPHENYLALANINE AND 6- [18F] FLUORO-L-META-TYROSINE AN

Disclosed is a method for producing precursors for 2-[18F]fluorophenylalanine and 6-[18F]fluoro-L-meta-tyrosine and the α-methylated derivatives thereof, to the precursor, and to a method for producing 2-[18F]fluorophenyla

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.

BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula (I), methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula (I), or compositions including them, to a subject. The invention also comprises further embodiments of Formulas (II) and (III), intermediates and processes useful for the preparation of compounds of the invention.

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.